Cargando…

Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases

Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hai, Yang, Jianqiong, Yang, Wanqing, Hu, Shaonan, Wu, Yali, Zhao, Bo, Hu, Haiyan, Du, Shouying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012233/
https://www.ncbi.nlm.nih.gov/pubmed/32103897
http://dx.doi.org/10.2147/DDDT.S240511
_version_ 1783496201189982208
author Liu, Hai
Yang, Jianqiong
Yang, Wanqing
Hu, Shaonan
Wu, Yali
Zhao, Bo
Hu, Haiyan
Du, Shouying
author_facet Liu, Hai
Yang, Jianqiong
Yang, Wanqing
Hu, Shaonan
Wu, Yali
Zhao, Bo
Hu, Haiyan
Du, Shouying
author_sort Liu, Hai
collection PubMed
description Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovascular protection, neuro-protection, anti-diabetes, liver protection, gastrointestinal protection, lung protection, bone metabolism regulation, renal protection, and anti-cancer. The metabolites produced by deglycosylation of NG-R1 exhibit higher permeability and bioavailability. It has been extensively verified that NG-R1 may ameliorate ischemia-reperfusion (IR)-induced injury in cardiovascular and neuronal systems mainly by upregulating the activity of estrogen receptor α-dependent phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor erythroid-2-related factor 2 (NRF2) pathways and downregulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. However, no specific targets for NG-R1 have been identified. Expectedly, NG-R1 has been used as a main bioactive compound in many Traditional Chinese Medicines clinically, such as Xuesaitong, Naodesheng, XueShuanTong, ShenMai, and QSYQ. These suggest that NG-R1 exhibits a significant potency in drug development.
format Online
Article
Text
id pubmed-7012233
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70122332020-02-26 Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases Liu, Hai Yang, Jianqiong Yang, Wanqing Hu, Shaonan Wu, Yali Zhao, Bo Hu, Haiyan Du, Shouying Drug Des Devel Ther Review Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovascular protection, neuro-protection, anti-diabetes, liver protection, gastrointestinal protection, lung protection, bone metabolism regulation, renal protection, and anti-cancer. The metabolites produced by deglycosylation of NG-R1 exhibit higher permeability and bioavailability. It has been extensively verified that NG-R1 may ameliorate ischemia-reperfusion (IR)-induced injury in cardiovascular and neuronal systems mainly by upregulating the activity of estrogen receptor α-dependent phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor erythroid-2-related factor 2 (NRF2) pathways and downregulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. However, no specific targets for NG-R1 have been identified. Expectedly, NG-R1 has been used as a main bioactive compound in many Traditional Chinese Medicines clinically, such as Xuesaitong, Naodesheng, XueShuanTong, ShenMai, and QSYQ. These suggest that NG-R1 exhibits a significant potency in drug development. Dove 2020-02-07 /pmc/articles/PMC7012233/ /pubmed/32103897 http://dx.doi.org/10.2147/DDDT.S240511 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Liu, Hai
Yang, Jianqiong
Yang, Wanqing
Hu, Shaonan
Wu, Yali
Zhao, Bo
Hu, Haiyan
Du, Shouying
Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases
title Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases
title_full Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases
title_fullStr Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases
title_full_unstemmed Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases
title_short Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases
title_sort focus on notoginsenoside r1 in metabolism and prevention against human diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012233/
https://www.ncbi.nlm.nih.gov/pubmed/32103897
http://dx.doi.org/10.2147/DDDT.S240511
work_keys_str_mv AT liuhai focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases
AT yangjianqiong focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases
AT yangwanqing focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases
AT hushaonan focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases
AT wuyali focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases
AT zhaobo focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases
AT huhaiyan focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases
AT dushouying focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases